Annual report pursuant to Section 13 and 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

v3.22.1
License, Clinical Trial and Sponsored Research Agreements (Tables)
12 Months Ended
Dec. 31, 2021
License Agreements [Member]  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of License, Clinical Trial and Sponsored Research Agreements

For the years ended December 31, 2021 and 2020, the Company recorded the following expense in research and development for licenses acquired:

For the year ended December 31, 

($ in thousands)

    

2021

    

2020

City of Hope National Medical Center

CD123

$

250

$

334

CS1

200

IL13Rα2

333

Spacer

333

PSCA

250

200

HER2

500

CSL Behring (Calimmune)

30

170

Leiden University Medical Centre

350

Fred Hutchinson Cancer Research Center - CD20

300

Mayo Clinic

750

SIRION Biotech LentiBOOSTTM

117

Fortress PIK Dividend

4,212

7,577

Total

$

5,842

$

10,064

Sponsored Research and Clinical Trial Agreements [Member]  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of License, Clinical Trial and Sponsored Research Agreements

For the year ended December 31, 2021 and 2020, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

For the year ended December 31, 

($ in thousands)

    

2021

    

2020

City of Hope National Medical Center

$

$

500

CD123

301

433

IL13Rα2

1,169

530

CS1

608

885

HER2

697

1,519

PSCA

107

204

Fred Hutchinson Cancer Research Center - CD20

1,979

1,804

St. Jude Children's Research Hospital - XSCID

865

1,842

LUMC - RAGI SCID

170

Mayo Clinic

695

Total

$

6,591

$

7,717